Updated contact details of KMP authorised to decide materiality and make disclosures
Alembic Pharmaceuticals has updated the contact details of the Key Managerial Personnel authorised to decide what is 'material' and to make disclosures to the stock exchanges.
By ScoutQuest · · 1 min read
- Board approval date
- 4th November, 2026
- KMP authorised for materiality and disclosures
- Mr. Chirayu Amin (Executive Chairman), Mr. Pranav Amin and Mr. Shaunak Amin (Managing Directors), Mr. G. Krishnan (CFO)
- Authorised for disclosures to stock exchanges
- Mr. Chirag K. Shukla, Company Secretary
What the update says
Alembic Pharmaceuticals has shared updated contact details of the persons authorised to decide whether an event or information is material, and to make disclosures to the stock exchanges. The Board of Directors approved this at its meeting held on 4th November, 2026.
Who is authorised
- Mr. Chirayu Amin, Executive Chairman
- Mr. Pranav Amin, Managing Director
- Mr. Shaunak Amin, Managing Director
- Mr. G. Krishnan, Chief Financial Officer
- Mr. Chirag K. Shukla, Company Secretary
The first four are listed as authorised both to determine materiality of an event or information and to make disclosures to the stock exchanges. The Company Secretary is listed as authorised to make disclosures to the stock exchanges.
What 'materiality' means here
Listed companies must tell the exchanges about events or information that a reasonable investor would consider important for an investment decision. Companies designate specific senior people who decide whether a given development crosses that bar. This update simply updates who those people are and how to reach them.
How to read this
- It is a routine governance update, not a business development.
- It names no financial figures, orders, products or transactions.
- The practical takeaway for a retail investor is limited to knowing who signs off on what the company discloses to the exchanges.
Also from Alembic Pharmaceuticals
Alembic Pharmaceuticals submits audio recording of 4th November, 2026 post results conference call
4 Nov 2026
Alembic Pharma reported strong Q2 results with revenue up 36%, profit up around 81% and sharp improvement in EBITDA margins, driven by US formulations growth
4 Nov 2026
Alembic Pharmaceuticals expands strategic collaboration with DifGen Pharmaceuticals for its US complex generics portfolio
4 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.